Gemfibrozil and Mediterranean diet for patients with high plasma levels of lipoprotein [Lp(a)] and cholesterol--pilot study
| Autor: | Dario Civalleri, Antonella Baiardi, G. Simoni, Alfredo Ardia, Aldo Gianotti |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Male
medicine.medical_specialty Mediterranean diet medicine.medical_treatment Hypercholesterolemia Enzyme-Linked Immunosorbent Assay Pilot Projects Epigastric pain Gastroenterology chemistry.chemical_compound Risk Factors Internal medicine medicine Gemfibrozil Humans Pharmacology (medical) Risk factor Triglycerides Aged Apolipoproteins B Pharmacology Chemotherapy biology Cholesterol business.industry Cholesterol HDL General Medicine Lipoprotein(a) Cholesterol LDL Endocrinology chemistry High plasma Chemotherapy Adjuvant biology.protein Female Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Cardiovascular drugs and therapy. 9(2) |
| ISSN: | 0920-3206 |
| Popis: | Plasma levels of lipoprotein-a [Lp(a)] > 30 mg/dl represent an independent risk factor for cardiovascular diseases with both proatherosclerotic and prothrombotic activity. The results of dietary or pharmacological treatment are not encouraging and are often controversial. We have evaluated a combination of medical treatment with Gemfibrozil (600 mg bid) and a Mediterranean diet for 2 months in 15 patients with both hypercholesterolemia (> 240 mg/dl) and high levels of Lp(a) (> 30 mg/dl). Three patients dropped out within the first 2 weeks, complaining of epigastric pain and burning; the remainder (5 females and 7 males, mean age 70 years) completed the treatment without any side effects. The median values of Lp(a) decreased from 36.5 to 8.4 mg/dl (p < 0.0002) and total cholesterol from 254.5 to 208.0 mg/dl (p < 0.0001). The small number of patients does not permit any definitive conclusion on effectiveness to be drawn, but the results indicate further randomized studies might prove worthwhile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink